Sartori's Boston mandate telemetry across 26 closed Associate Recruiting searches records that 9 of those files targeted Venture Capital, emerging-company or company-side financing seats, and 7 of the 9 asked for class years 3–6 with preferred-stock, SPA or life-sciences collaboration ownership. Juniors (years 1–2) still arrive mainly through campus and clerkship pipelines at lockstep platforms; pure junior laterals stay secondary when NALP reports direct-to-clerkship hiring up about 17% nationally in 2025. Mid-levels own the bandwidth market: term-sheet markup, preferred-stock certificates, disclosure schedules, investor-side side letters and company-side Series B–D workstreams already mid-pipeline.
Seniors and counsel-track lawyers (years 6–8) move when a multi-partner Venture Capital pod needs a second who can supervise two juniors and hold client calls on late-stage or secondary packages—or when a biotech general counsel's office returns a senior associate to firm practice after a financing cycle. A hiring partner at a national Am Law Boston emerging-company desk told us a year-4 with two signed preferred-stock closings on therapeutic issuers beats a year-5 with diligence-only history when the group is mid-financing—and that ownership filter still loses to the therapeutic portfolio grid if multi-office pharma walls overlap.
Supply thins where company-side venture, growth equity, biotech corporate and PE pull the same mid-level names. Platforms with meaningful Boston Venture Capital depth—Goodwin, Cooley, WilmerHale, Ropes & Gray, Mintz, Foley Hoag, Latham & Watkins, Kirkland & Ellis and peer national shops—set process norms. Expanding platforms hire against that benchmark when they need one portable financing mid-level, not another summer class of six.
